RCKT
Price
$3.45
Change
-$0.18 (-4.96%)
Updated
Dec 11 closing price
Capitalization
373.37M
80 days until earnings call
Intraday BUY SELL Signals
SPRO
Price
$2.35
Change
+$0.02 (+0.86%)
Updated
Dec 11 closing price
Capitalization
132.4M
104 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RCKT vs SPRO

Header iconRCKT vs SPRO Comparison
Open Charts RCKT vs SPROBanner chart's image
Rocket Pharmaceuticals
Price$3.45
Change-$0.18 (-4.96%)
Volume$8.12M
Capitalization373.37M
Spero Therapeutics
Price$2.35
Change+$0.02 (+0.86%)
Volume$186.05K
Capitalization132.4M
RCKT vs SPRO Comparison Chart in %
View a ticker or compare two or three
VS
RCKT vs. SPRO commentary
Dec 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCKT is a Buy and SPRO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 13, 2025
Stock price -- (RCKT: $3.45 vs. SPRO: $2.35)
Brand notoriety: RCKT and SPRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RCKT: 329% vs. SPRO: 25%
Market capitalization -- RCKT: $373.37M vs. SPRO: $132.4M
RCKT [@Biotechnology] is valued at $373.37M. SPRO’s [@Biotechnology] market capitalization is $132.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $113.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RCKT’s FA Score shows that 1 FA rating(s) are green whileSPRO’s FA Score has 1 green FA rating(s).

  • RCKT’s FA Score: 1 green, 4 red.
  • SPRO’s FA Score: 1 green, 4 red.
According to our system of comparison, SPRO is a better buy in the long-term than RCKT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCKT’s TA Score shows that 5 TA indicator(s) are bullish while SPRO’s TA Score has 4 bullish TA indicator(s).

  • RCKT’s TA Score: 5 bullish, 4 bearish.
  • SPRO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, RCKT is a better buy in the short-term than SPRO.

Price Growth

RCKT (@Biotechnology) experienced а +0.88% price change this week, while SPRO (@Biotechnology) price change was +3.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.31%. For the same industry, the average monthly price growth was +4.75%, and the average quarterly price growth was +65.86%.

Reported Earning Dates

RCKT is expected to report earnings on Mar 02, 2026.

SPRO is expected to report earnings on Mar 26, 2026.

Industries' Descriptions

@Biotechnology (+1.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCKT($373M) has a higher market cap than SPRO($132M). SPRO YTD gains are higher at: 128.155 vs. RCKT (-71.122). SPRO has higher annual earnings (EBITDA): -56.36M vs. RCKT (-245.09M). RCKT has more cash in the bank: 271M vs. SPRO (31.2M). SPRO has less debt than RCKT: SPRO (3.62M) vs RCKT (25.2M). SPRO has higher revenues than RCKT: SPRO (34.1M) vs RCKT (0).
RCKTSPRORCKT / SPRO
Capitalization373M132M283%
EBITDA-245.09M-56.36M435%
Gain YTD-71.122128.155-55%
P/E RatioN/A10.75-
Revenue034.1M-
Total Cash271M31.2M869%
Total Debt25.2M3.62M697%
FUNDAMENTALS RATINGS
RCKT vs SPRO: Fundamental Ratings
RCKT
SPRO
OUTLOOK RATING
1..100
577
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
6045
P/E GROWTH RATING
1..100
1006
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCKT's Valuation (13) in the Biotechnology industry is somewhat better than the same rating for SPRO (60) in the Pharmaceuticals Major industry. This means that RCKT’s stock grew somewhat faster than SPRO’s over the last 12 months.

RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SPRO (100) in the Pharmaceuticals Major industry. This means that RCKT’s stock grew similarly to SPRO’s over the last 12 months.

RCKT's SMR Rating (97) in the Biotechnology industry is in the same range as SPRO (98) in the Pharmaceuticals Major industry. This means that RCKT’s stock grew similarly to SPRO’s over the last 12 months.

SPRO's Price Growth Rating (45) in the Pharmaceuticals Major industry is in the same range as RCKT (60) in the Biotechnology industry. This means that SPRO’s stock grew similarly to RCKT’s over the last 12 months.

SPRO's P/E Growth Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for RCKT (100) in the Biotechnology industry. This means that SPRO’s stock grew significantly faster than RCKT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RCKTSPRO
RSI
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
73%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 9 days ago
77%
Bullish Trend 4 days ago
70%
Declines
ODDS (%)
Bearish Trend 23 days ago
86%
Bearish Trend 17 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 8 days ago
82%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
RCKT
Daily Signal:
Gain/Loss:
SPRO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MOORX18.520.26
+1.42%
MassMutual Small Cap Opps R4
FLEKX12.940.10
+0.78%
Victory Pioneer Equ Premium Income R6
RPBAX29.990.21
+0.71%
T. Rowe Price Balanced
PLSHX10.000.02
+0.20%
Aristotle Strategic Income H
MSCMX18.00N/A
N/A
Morgan Stanley Insight C

RCKT and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCKT has been loosely correlated with SVRA. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if RCKT jumps, then SVRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCKT
1D Price
Change %
RCKT100%
+8.04%
SVRA - RCKT
59%
Loosely correlated
+3.72%
PRTA - RCKT
54%
Loosely correlated
-4.36%
AXON - RCKT
52%
Loosely correlated
+3.98%
VCYT - RCKT
47%
Loosely correlated
-1.16%
RGNX - RCKT
43%
Loosely correlated
+2.67%
More

SPRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with ASBP. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then ASBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
+0.86%
ASBP - SPRO
58%
Loosely correlated
+22.51%
CLGN - SPRO
38%
Loosely correlated
+4.97%
XENE - SPRO
32%
Poorly correlated
+0.51%
MGTX - SPRO
30%
Poorly correlated
+3.93%
MTVA - SPRO
30%
Poorly correlated
-10.37%
More